PE Deals

PAI looking at 3.7x return with ELITech sale

Bruker Corporation has signed an agreement with the private equity firm that includes a put option to buy ELITech.

-
  • ELITech is an in-vitro diagnostic company
  • Hospitals and laboratories in more than 100 countries use ELITech’s products
  • PAI invested in the business in 2017

UPDATED. PAI Partners will hit a 3.7x gross multiple on its investment in in-vitro diagnostic company ELITech Group if a potential sale to Bruker Corporation goes ahead.

Share this